doi: 10.3389/fphar.2025.1654372 Received 26 June 2025 Accepted 05 August 2025 Published 18 August 2025 Volume 16 - 2025 Edited by Abbas Choudhury, VIT University, India Reviewed by Evelyn Weaver, The Pennsylvania State University (PSU), United States Marcelo Adrian Estrin, Interamerican Open University, Argentina Updates Copyright 2025 Zeng, Luo, Ou, Gan, Huang, Tomlinson and Jiang
Recent studies highlight how GLP-1 receptor agonistsincluding Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound)exhibit powerful anti-inflammatory effects
Sweating is a recognized but often temporary side effect that responds well to hydration, lifestyle adjustments, and dose timing strategies
JAMA 318(15):14601470 Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrges JP, Lindegaard ML, Jensen CB, Atkin SL (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
